Nicolai Wagtmann joined Innate Pharma in September 2013. He brings significant biopharmaceutical research and development experience to the company, having spent 14 years in the R&D organization at Novo Nordisk A/S, where he built a portfolio of first-in-class therapeutic antibodies for treatment of cancer and chronic inflammatory diseases.
In 2005 he was appointed Vice President and Head of Inflammation Biology and member of the Biopharmaceuticals Research Unit management team, with global responsibilities for Novo Nordisk A/S’s portfolio of biopharmaceuticals in immunology, growth hormone and hemophilia. Prior to that, he held roles as Director of Cancer & Immunobiology and other management roles at Novo Nordisk A/S. Nicolai Wagtmann received his Ph.D. in immunology from the University of Copenhagen.
From 1991-1998, he held academic appointments at the National Institutes of Health, USA and the Center for Immunology in Marseille, France.